Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. FL Rosenfeldt1,2,3, SJ Haas4,5, H Krum4,5, A Hadj1,3, K Ng1, J-Y Leong1,3 and GF Watts6

Coenzyme Q10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects. This meta-analysis encompassed all published studies of CoQ10 in the treatment of hypertension and found a blood pressure lowering effect across all studies.The prospective randomized studies and the
crossover study showed similar results. Among treated patients, decreases in systolic blood pressure ranged from 11 mm Hg in the crossover study to 17 mm Hg in the group of randomized studies. A decrease of 8 mm Hg in diastolic blood pressure was observed in the treated patients of both the crossover study and in the randomized trials.The open label observational studies, of which the largest stud comprised 109 patients, were before and-after studies without a placebo control group and included the earliest studies dating from 1975.
All these studies showed significant decreases in blood pressure ranging from 10 to 21 mm Hg systolic and from 7 to 16 mm Hg diastolic that were similar in magnitude to the randomized studies. These represent credible therapeutic effects given that the placebo group in the randomized studies showed decreases in systolic blood pressure of only 1–4 mm Hg systolic and 0–3 mm Hg diastolic